Jump to content

Search the Community

Showing results for tags 'arn-509'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 2 results

  1. "It is clear from these data that apalutamide has activity in the treatment of men with nmCRPC. This is not a surprise. However, the degree of promise for apalutamide based on these data (compared to other drugs already available on the market) is much harder to evaluate. Would treatment of this set of patients with either enzalutamide or abiraterone acetate have shown similar outcomes? We really don’t know." Click on this link to read an article in the New Prostate Cancer Infolink about a recent Phase II trial.
  2. Paul Edwards

    New Clinical Trial of JNJ-56021927

    JNJ-56021927 (formerly known as ARN-509) is an androgen receptor antagonist. Some prostate cancer cells require androgens for growth. JNJ-56021927 prevent androgens from binding to the prostate cancer cells’ androgen receptors. JNJ-56021927 is not as advanced in its development as enzalutamide (Brand name Xtandi). Results from initial clinical trials suggest that JNJ-56021927 may be more potent and effective than enzalutamide. A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer is being conducted. Details of this trial can be found by clicking on this link: https://clinicaltrials.gov/ct2/show/NCT02257736 This clinical trial is being conducted at a number of hospitals in most Australian states. I am aware that the Royal Melbourne Hospital has commenced recruitment of patients for this trial. I'm not aware of the recruitment status of the other Australian sites but I expect that these sites will commence recruitment shortly, if they are not already doing so. There will be 2 arms of the trial. Patients on the 1st arm will receive Abiraterone, Prednisone and JNJ-56021927. Patients on the 2nd arm will receive Abiraterone, Prednisone and a placebo.
×
×
  • Create New...